Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Her2 Positive Metastatic Breast Cancer”

959 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 959 results

Testing effectiveness (Phase 2)Study completedNCT03659136
What this trial is testing

The XENERA™ 1 Study Tests Xentuzumab in Combination With Everolimus and Exemestane in Women With Hormone Receptor Positive and HER2-negative Breast Cancer That Has Spread

Who this might be right for
Breast Neoplasms
Boehringer Ingelheim 103
Testing effectiveness (Phase 2)Study completedNCT00337649
What this trial is testing

Epothilone D in Combination With Herceptin (Trastuzumab) in Patients With HER-2 Positive Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Hoffmann-La Roche 27
Large-scale testing (Phase 3)Study completedNCT00103233
What this trial is testing

Vinorelbine With or Without Trastuzumab in Treating Women With Progressive Metastatic Breast Cancer

Who this might be right for
Breast Cancer
SWOG Cancer Research Network
Testing effectiveness (Phase 2)Study completedNCT00386685
What this trial is testing

XRP9881 in Combination With Trastuzumab in Metastatic Breast Cancer

Who this might be right for
Breast Neoplasms
Sanofi 51
Testing effectiveness (Phase 2)Study completedNCT00526045
What this trial is testing

Phase I-II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 in Advanced Solid Malignancies, and Efficacy in HER2+ or ER+ Locally Advanced or Metastatic Breast Cancer Patients

Who this might be right for
Breast CancerHematologic Neoplasms
Novartis Pharmaceuticals 117
Not applicableLooking for participantsNCT06299852
What this trial is testing

Stereotactic Radiation Therapy for HE2-positive Oligometastatic Breast Cancer

Who this might be right for
HER2-positive Metastatic Breast CancerOligometastatic Disease
N.N. Petrov National Medical Research Center of Oncology 58
Testing effectiveness (Phase 2)Study completedNCT02362958
What this trial is testing

A Multi-Center Study of Lapatinib in Patients With Trastuzumab-refractory Metastatic Breast Cancer

Who this might be right for
HER2 Positive Breast Cancer
Sun Yat-sen University 159
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06595563
What this trial is testing

HER2 Molecular Imaging With 89Zr-trastuzumab PET/CT as a Predictive Biomarker for Antibody-drug Conjugate Sequencing in Patients With Advanced HER2-positive Breast Cancer

Who this might be right for
HER2-positive Metastatic Breast CancerHER2-positive Advanced Breast Cancer
Jules Bordet Institute 87
Testing effectiveness (Phase 2)Looking for participantsNCT07053085
What this trial is testing

Surgery and Radiotherapy in People With Breast Cancer

Who this might be right for
Metastatic Breast CancerHER2-positive Breast Cancer
Memorial Sloan Kettering Cancer Center 162
Testing effectiveness (Phase 2)Active Not RecruitingNCT03414658
What this trial is testing

The AVIATOR Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast Cancer

Who this might be right for
Breast Cancer
Adrienne G. Waks 100
Large-scale testing (Phase 3)Ended earlyNCT01303679
What this trial is testing

1st Line Treatment of Bevacizumab-Taxane vs Bevacizumab-Exemestane in Metastatic Breast Cancer

Who this might be right for
First Line Metastatic Breast Cancer
ARCAGY/ GINECO GROUP 117
Testing effectiveness (Phase 2)Active Not RecruitingNCT04576455
What this trial is testing

A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer)

Who this might be right for
Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer
Hoffmann-La Roche 303
Early research (Phase 1)Study completedNCT04367090
What this trial is testing

Pharmacokinetic Study of Pyrotinib and Docetaxel in Combination With Trastuzumab in Patients With HER2 Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Jiangsu HengRui Medicine Co., Ltd. 97
Testing effectiveness (Phase 2)Ended earlyNCT00079326
What this trial is testing

Trastuzumab and Ixabepilone in Treating Women With HER2-Positive Metastatic Breast Cancer

Who this might be right for
HER2-positive Breast CancerRecurrent Breast CancerStage IV Breast Cancer
National Cancer Institute (NCI) 39
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07164976
What this trial is testing

Ribociclib for HR-positive HER2-negative Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Nagoya City University 86
Early research (Phase 1)Study completedNCT01423123
What this trial is testing

Combination of Weekly Paclitaxel With Neratinib and Trastuzumab in Women With Metastatic HER2-positive Breast Cancer

Who this might be right for
Breast Cancer
NSABP Foundation Inc 21
Testing effectiveness (Phase 2)Study completedNCT00411788
What this trial is testing

A Phase II Study of Rapamycin and Trastuzumab for Patients With HER-2 Receptor Positive Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Yale University 11
Testing effectiveness (Phase 2)Study completedNCT01306942
What this trial is testing

Dasatinib In Combination With Trastuzumab And Paclitaxel In First Line Treatment Of Her2-Positive MBC Patients

Who this might be right for
Metastatic Breast Cancer
Spanish Breast Cancer Research Group 37
Early research (Phase 1)Study completedNCT04509596
What this trial is testing

DZD1516 in Combination With Trastuzumab and Capecitabine, or in Combination With T-DM1, in Patients With Metastatic HER2 Positive Breast Cancer

Who this might be right for
Breast Cancer Metastatic
Dizal Pharmaceuticals 23
Testing effectiveness (Phase 2)Active Not RecruitingNCT04538742
What this trial is testing

A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
AstraZeneca 245
Load More Results